<DOC>
	<DOCNO>NCT01313455</DOCNO>
	<brief_summary>Background : - Polycystic ovarian syndrome ( PCOS ) group disorder relate problem secretion certain hormone , lead reproductive issue woman . Frequent complication PCOS include irregular menstruation , development ovarian cyst , insulin resistance . The adrenal gland , sit top kidney , involve production certain hormone regulation steroid level blood , may affect woman PCOS . Researchers interested study possible connection adrenal gland PCOS young woman diagnose PCOS healthy volunteer normal menstrual function . Objectives : - To investigate possible connection adrenal gland steroid hormone secretion polycystic ovarian syndrome . Eligibility : - Women 16 29 year age diagnose PCOS , healthy volunteer normal menstrual function . - Participants must willing discontinue use oral contraceptive medication alter steroid hormone production least 1 month start study . Design : - Participants screen physical examination , medical history , blood urine test . All participant also pelvic ( ovarian ) ultrasound . - All participant admit hospital 1-week testing period , involve follow test : - Regular blood draw two 2-hour period ( late evening early morning ) measure hormone level - Fasting blood draw dose corticotropin test body 's adrenal function - Hormone level measurement follow regular dos dexamethasone ( drug control function adrenal gland ) - Daily urine collection 6 day . - Other study , image study adrenal gland , may conduct require study researcher .</brief_summary>
	<brief_title>Adrenal Hyperplasia Among Young People With PCOS</brief_title>
	<detailed_description>Polycystic ovarian syndrome ( PCOS ) heterogeneous group disorder present hyperandrogenism adolescent young woman . The etiology condition remain unknown , despite many identified link insulin resistance , hypertension metabolic syndrome , well potential connection various form congenital adrenal hyperplasia ( CAH ) . The adrenal gland source body adrenocortical steroid . In normal physiology , pituitary hormone ACTH regulate secretion glucocorticoid , secretion mineralocorticoid control renin-angiotensin system . In addition two steroid , adrenal gland secretes lesser amount intermediate metabolite steroid , well sex-steroids DHEA , DHEAS , androstenedione , testosterone , estrogen , estrone . Dysregulated secretion hormone cause development hyperplasia adrenocortical tissue , may mild lead specific clinical syndrome depend identity secrete hormone . Bilateral adrenocortical hyperplasia ( BAH ) increasingly diagnose cause adrenal dysfunction . We propose subgroup patient PCOS actually non-CAH primary form BAH . To investigate possibility , propose study hypothalamic-pituitary-adrenal axis ( HPAA ) next 2 year 120 young girl woman ( age 16 25 year ) compare 30 age- race-matched normal female . Patients recruit primarily ( although exclusively ) busy New York City clinic run Pediatric Endocrine Division Infants Children 's Hospital Brooklyn Maimonides SUNY Downstate . All patient undergo standard test HPAA include oral low- high-dose dexamethasone ( DEX ) -suppression test ( Liddle test ) . Paradoxical rise cortisol and/or steroid metabolites response DEX consider sensitive test diagnosis BAH . Patients responses molecularly investigate know cause BAH ( GNAS , PRKAR1A , PDE11A , PDE8B mutation ) . The first goal study identify possible contribution BAH phenotypes genotype pathophysiology PCOS , yet unknown factor etiology multifaceted disorder . The second goal perform comparative analysis expression large set gene cell patient use gene array genetic analysis . This study generate important information molecular pathway affect subgroup patient PCOS . Thirdly , study also allow collection DNA affect non-affected relative patient perform genetic study identify causative genetic defect . Finally , study expect lead new diagnostic therapeutic method least certain form PCOS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hyperandrogenism</mesh_term>
	<mesh_term>Oligomenorrhea</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>INCLUSION CRITERIA FOR PATIENTS : Women 1624 year old PCOS define biochemical hyperandrogenism associate finding either menstrual irregularity /or polycystic ovary ultrasound ; hyperandrogenism define elevation follow androgen : free testosterone , total testosterone , DHEAS , DHEA , 17 0H progesterone , androstenedione , 17OH pregnenolone ; polycystic ovary ultrasound either 12 follicle measure 29 mm diameter , increase ovarian volume 10 CC great ; menstrual irregularity define : Amenorrhea refers absence bleed least three usual cycle length ; oligomenorrhea refers bleed occurs interval great 35 day . We would like patient oligomenorrhea least six usual cycle length . Patients oral contraceptive pill medication alter steroidogenesis least one month prior participate study INCLUSION CRITERIA FOR CONTROLS : Women 1825 year old normal menstrual function ; oral contraceptive pill medication alter steroidogenesis least one month prior participate study . EXCLUSION CRITERIA FOR PATIENTS : Patients hyperandrogenism due 21 hydroxylase deficiency non classic adrenal hyperplasia androgen secrete neoplasms Women know suspected androgenic/anabolic drug use Women severe insulin resistanceacanthosis nigricans syndrome ; Fasting insulin level obtain rule syndrome severe insulin resistance hyperandrogenism ; insulin 80 mU/mL fast state , and/or &gt; 300 mU/mL follow 2 3hour oral glucose tolerance test ( obtain elsewhere ) , patient eligible . Women thyroid dysfunction , hyperprolactinemia , ( define prolactin level great equal 3 time upper reference limit ) , less 2 year post menarche , patient medication alter steroidogenesis oral contraceptive pill , less month prior date inclusion study . ( see : patient oral contraceptive pill medication alter steroidogenesis least one month prior participate study ) Women prior history pregnancy . EXCLUSION CRITERIA FOR CONTROLS : Young woman hyperandrogenemia , hirsutism know adrenal tumor endocrine disease , patient multiple medication , know insulin resistance , chronic acute illness eligible control study .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>September 30, 2016</verification_date>
	<keyword>Oligomenorrhea</keyword>
	<keyword>Adrenal Hyperplasia</keyword>
	<keyword>Obesity</keyword>
	<keyword>Hyperandrogenism</keyword>
	<keyword>Polycystic Ovarian Syndrome</keyword>
	<keyword>PCOS</keyword>
	<keyword>Polycystic Ovary</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>